2. Search Result
Search Result
Results for "

JIMT-1

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

2

Inhibitory Antibodies

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99030
    Margetuximab

    		EGFR Cancer
    Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC50 value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer [1].
    Margetuximab
  • HY-153065
    KIF18A-IN-6

    		Microtubule/Tubulin Cancer
    KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor with an IC50 of 0.016 μM against KIF18A microtubule-dependent ATPase activity [1].
    KIF18A-IN-6
  • HY-153066
    KIF18A-IN-7

    		Microtubule/Tubulin Cancer
    KIF18A-IN-7 (Compound 22) is an orally active KIF18A inhibitor with an IC50 of 9.4 nM against KIF18A microtubule-dependent ATPase activity [1].
    KIF18A-IN-7
  • HY-P99969
    Inetetamab

    		EGFR Cancer
    Inetetamab is a monoclonal antibody binding to domain IV of HER2 receptor. Inetetamab alone or together with tyrosine kinase inhibitors has antitumor activities [1] .
    Inetetamab
  • HY-N1305
    Sideritoflavone

    Sideritiflavone

    		 Others Cancer
    Sideritoflavone is a flavonoid. Sideritoflavone can be isolated from Baccharis densiflora. Sideritoflavone is toxic to JIMT-1 breast cancer cells [1].
    Sideritoflavone
  • HY-161781
    HVH-2930

    		HSP EGFR Akt Survivin Cancer
    HVH-2930 is an inhibitor for heat shock protein 90 (HSP90). HVH-2930 inhibits cell viability of BT474 (Trastuzumab (HY-P9907) sensitive) and JIMT-1 (Trastuzumab (HY-P9907) resistant), with IC50 of 6.86 μM and 4.42 μM, through downregulation of HSP90 clients HER2, p-HER2, AKT, p-AKT, cyclin D1 and survivin. HVH-2930 exhibits antitumor efficacy in mouse models. HVH-2930 exhibits good pharmacokinetic characteristics in mice [1].
    HVH-2930
  • HY-152208
    BPDA2

    		SHP2 Cancer
    BPDA2 is a highly selective and competitive active site SHP2 inhibitor with IC50s of 92.0 nM, 33.39 μM, 40.71 μM for SHP2, SHP1, SHP1B, respectively. DBDA2 downregulates mitogenic and cell survival signaling and RTK expression. BPDA2 suppresses SHP2 mediated signaling and breast cancer cell phenotypes [1].
    BPDA2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: